Korean FDA approves STAAR Surgical's TICL
Monrovia, CA—STAAR Surgical Co. said it has received approval from the Korean Food and Drug Administration (KFDA) to market the STAAR Visian Toric lens (TICL) in South Korea.
Monrovia, CA-STAAR Surgical Co. said it has received approval from the Korean Food and Drug Administration (KFDA) to market the STAAR Visian Toric lens (TICL) in South Korea.
The TICL is the first myopic ICL to receive KFDA approval, according to the company.
"This product will allow us to serve a broader population and further build our presence in our second-largest market for the myopic ICL," said David Bailey, president and chief executive officer of STAAR Surgical. The new market should provide a "meaningful increase" to the company's refractive business, he added.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
.png "Optometry Times"){kind=logo}
